Search research articles
Contact Us
Filters
Showing results (201-210 of 210) with videos related to
Page
of 21
Sort By:
You have reached the last page of results.
This site can display upto 210 results.
Cancer Cell
|
January 12, 2024
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
Danish Memon, Adam J Schoenfeld, Darwin Ye, et al.
Nature Communications
|
July 2, 2025
Divergent trajectories to structural diversity impact patient survival in high grade serous ovarian cancer
Ailith Ewing, Alison Meynert, Ryan Silk, et al.
Cancer Cell
|
July 11, 2025
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer
Ana Galan-Cobo, Natalie I Vokes, Yu Qian, et al.
EMBO Molecular Medicine
|
November 1, 2018
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Marta Castroviejo-Bermejo, Cristina Cruz, Alba Llop-Guevara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2017
AKT Inhibition in Solid Tumors With AKT1 Mutations
David M Hyman, Lillian M Smyth, Mark T A Donoghue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2022
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Violeta Serra, Anderson T Wang, Marta Castroviejo-Bermejo, et al.
Nature Medicine
|
February 13, 2024
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 4, 2021
Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project
D M Vega, L M Yee, L M McShane, et al.
Nature Communications
|
February 24, 2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment
Elizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, et al.
Nature
|
April 13, 2023
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Christopher Abbosh, Alexander M Frankell, Thomas Harrison, et al.
Page
of 21
Search research articles
Search
Showing results (201-210 of 210) with videos related to
Sort By:
Page
of 21
You have reached the last page of results.
This site can display upto 210 results.
Cancer Cell
|
January 12, 2024
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
Danish Memon, Adam J Schoenfeld, Darwin Ye, et al.
Nature Communications
|
July 2, 2025
Divergent trajectories to structural diversity impact patient survival in high grade serous ovarian cancer
Ailith Ewing, Alison Meynert, Ryan Silk, et al.
Cancer Cell
|
July 11, 2025
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer
Ana Galan-Cobo, Natalie I Vokes, Yu Qian, et al.
EMBO Molecular Medicine
|
November 1, 2018
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Marta Castroviejo-Bermejo, Cristina Cruz, Alba Llop-Guevara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2017
AKT Inhibition in Solid Tumors With AKT1 Mutations
David M Hyman, Lillian M Smyth, Mark T A Donoghue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2022
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Violeta Serra, Anderson T Wang, Marta Castroviejo-Bermejo, et al.
Nature Medicine
|
February 13, 2024
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 4, 2021
Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project
D M Vega, L M Yee, L M McShane, et al.
Nature Communications
|
February 24, 2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment
Elizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, et al.
Nature
|
April 13, 2023
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Christopher Abbosh, Alexander M Frankell, Thomas Harrison, et al.
Page
of 21